An interventional study of Cruciferae intake diet and Habituary dietary regimen in Recurrence Free Survival and Bladder Cancer Recurrence, sponsored by S. Andrea Hospital. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by S. Andrea Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy — 12 open to participants now, 15 under way, 5 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Italy.
Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 27th registered.
295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →12 of the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
University of Roma La Sapienza · Sites in Italy
Ages 18+
Janssen Research & Development, LLC · Sites in Italy, United States, Argentina and 12 more countries
Ages 18+
Tyra Biosciences, Inc · Sites in Italy, United States, Australia and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Istituto Oncologico Veneto IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 8 · Phase 4 1
First in 1994; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 190 across the 27 interventional studies, 1,300 across the 3 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 30 have an industry lead sponsor. The 10 most frequent:
S. Andrea Hospital is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
S. Andrea Hospital has 1 study filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06245603Istituto Oncologico Veneto IRCCSA Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer | 2026-12 |
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids [10-13]. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC [14,15]. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase [16]. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis [17-22].
Aims Primary Objective
Secondary Objectives
Background Bladder cancer (BC) ranks as the seventh most common cancer among men globally and the tenth when both genders are considered. The majority (up to 75%) of newly diagnosed BC presents as non-muscle-invasive BC (NMIBC) including Ta (non-invasive papillary carcinoma confined to the mucosa), CIS (Carcinoma in Situ, a flat, high grade, non-invasive urothelial carcinoma) and T1 (tumor invasion of the sub-epithelial connective tissue) disease stage. NMIBC has a high prevalence due to low progression rates and long-term survival, representing a significant burden on both public health and individual well-being. The prevalence of urothelial BC is among the highest for all urologic malignancies. Although the understanding of genetic susceptibility is growing steadily, no clinically relevant genetic alteration has been linked to BC up to date, and family history seems to have little impact on BC risk. Conversely, most BC cases are associated with external exposure to carcinogens. Supportive evidence has been reported on several risk factors: tobacco smoking alone accounts for approximately 50% of events. In contrast, occupational exposure (mostly involving aromatic amines, polycyclic, and chlorinated hydrocarbons) represents the second most common risk factor in industrialized countries. Environmental exposure (e.g., trihalomethanes and arsenic in drinking water) and pelvic radiation have been linked to an increased risk of developing BC. In light of the significant impact of modifiable risk factors on the incidence of BC, implementation of primary prevention strategies can lead to a decrease in BC risk: in the "Women's Health Initiative (WHI) Study" a decrease in BC risk was demonstrated after smoking cessation. Likewise, work-safety guidelines have been prompted to reduce the extent of professional exposure in developed industrial settings, thus eliminating the difference in BC incidence between chemical workers and the general population. Primary interventions targeting exposure and lifestyle changes have become central to public health strategies aimed at mitigating the burden of bladder cancer. In the broader landscape of primary prevention, dietary habits play a crucial role in reducing the risk of bladder cancer. Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis. Several in vitro, in vivo, and epidemiologic studies have shown that a diet rich in vegetables in the Cruciferae family may lower overall cancer risk for breast, colorectal, lung, and prostate cancer. The important role of dietary ITCs has been demonstrated in reducing BC risk and BC-specific mortality. In vitro, the 4 most common dietary ITCs and their primary urinary metabolites showed inhibition of growth of a panel of human bladder cancer cells, including NMIBC cells, with half-maximal inhibitory concentration (IC50) values around 10 µmol on average, which is achievable in the urine with a single oral dose of ITC at 10 µmol/kg in rats, also readily achievable in humans, considering an average total isothiocyanate yield in Cruciferae of 16.2 μmol/100g wet weight. By increasing Cruciferae intake by 1 cup a day, the urinary concentration of ITCs increases on average by 10.4 µmol, the desirable dose level of urinary ITCs needed to stop or kill at least 50% of bladder cancer cells in in vitro models. Orally ingested ITCs are rapidly and almost exclusively delivered to the bladder and concentrated in the urine, showing concentration 2 or 3 times higher in the urine than in the plasma within 3 hours of dosing. This unique in vivo metabolism and disposition pathway renders the bladder the best target for ITCs' anticancer potential. In the Bladder Cancer Epidemiology, Wellness, and Lifestyle Study (Be-Well study), a multicenter prospective cohort study on newly diagnosed NMIBC, a possible beneficial role of dietary ITCs in NMIBC prognosis was assessed: despite no overall association between dietary ITC intake and recurrence risk was found, high ITC intake was linked to over twice the odds of late recurrence, while high raw cruciferous vegetable intake reduced the odds of multiple recurrences by 50%-60%, and elevated BITC and PEITC biomarkers were associated with >50% lower risk of muscle-invasive progression. In the same study group, the impact of dietary ITC exposure was assessed in relation to the efficacy of intravesical Mitomycin (MMC) chemotherapy or Bacillus Calmette-Guérin (BCG) immunotherapy on the risk of recurrence. In a stratified analysis, patients who received BCG and consumed high amounts (>2.4 servings/month with 1 serving corresponding to half a cup of non-leafy vegetables or 1 cup of leafy vegetables) of raw CVs had at least a 44% reduced risk of recurrence and multiple recurrences, which was not observed in those consuming low doses of row CV. In a randomized controlled setting, this study aims to assess the impact of CV intake and ITC exposure on recurrence risk in patients with NMIBC undergoing BCG intravesical immunotherapy.
Hypothesis Primary interventions targeting exposure and lifestyle changes have become central to public health strategies aimed at mitigating the burden of bladder cancer. In the broader landscape of primary prevention, dietary habits play a crucial role in reducing the risk of bladder cancer. Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis.
Aims Primary Objective
Secondary Objectives
Experimental design This study is a parallel-group, randomized controlled trial with a 1:1 allocation ratio designed to assess the superiority of a high-cruciferous vegetable dietary regimen compared to standard care in reducing bladder cancer recurrence.
Intervention The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB before randomization, and only subjects who fulfill the inclusion criteria will be included: patients with a diagnosis of Intermediate, High, and Very High-risk NMIBC, according to the new EAU NMIBC prognostic factor risk groups. Patients in the intervention group will receive a dietary regimen characterized by high consumption of Cruciferae vegetables [≥1 cup /day] for 6 months. Patients in this group will receive educative booklets on the Cruciferae family of vegetables and visual charts on serving sizing to meet the recommended daily CV intake. Patients will be asked to record daily Cruciferae intake. They will receive a live phone call every week to verify their understanding of the educational information and the consistency of the dietary regimen. Patients randomized in the control group will receive standard of care (SOC) without modifying the habitual nutritional regimen.
Study Timeline
Study Timeline Timepoint (mo) T0 1 2 3 4 5 6 7 8 9 10 11 12 ENROLMENT Eligibility screen X Informed Consent X Baseline clinical evaluation X Allocation X INTERVENTION Dietary Regimen vs SOC X X X X X X X ASSESSMENTS FU clinical evaluation X X X X FU phone call X X X X X X CLOSE-OUT X
Table 1. Study Timeline. Each participant will take part in the study for a total of 12 months after enrollment. Abbreviations: mo= months; FU= Follow-up.
Sample size A power analysis was conducted before data collection using SPSS to determine the appropriate sample size. A two-sided test with a Type I error rate (α) of 0.05 and a statistical power of 80% was performed to ensure adequate power for detecting a meaningful effect. The anticipated impact is the relative reduction of 40% (an absolute reduction of 10%) of the recurrence rate in the Study group versus the control group, given a recurrence rate in the general population (according to EAU risk stratification) of 25% at 1 year. To detect this difference, 250 patients per group are necessary, using the adjusted chi-square method.
Sequence generation and blinding The allocation sequence will be generated using computer-generated random numbers with a ratio of 1:1. This study will be conducted as an open-label trial. Due to the nature of the dietary intervention, neither participants nor study staff will be blinded to group assignment. However, outcome assessors analyzing urinary ITC levels and recurrence outcomes will be blinded to participant allocation.
Expected results The primary outcome of recurrence-free survival and the secondary outcome time to recurrence will be analyzed using Kaplan-Meier survival curves, and the intervention and control groups will be compared using the log-rank test. The Cox proportional hazards model will be applied to estimate hazard ratios, adjusting for relevant covariates such as age, gender, and baseline tumor characteristics. A two-tailed p-value \< 0.05 will be considered statistically significant. Secondary outcomes, including urinary ITC levels, will be analyzed using t-tests or Mann-Whitney U tests for continuous variables and Chi-squared tests for categorical variables, depending on the data distribution. Descriptive statistics (mean, median, standard deviation) will be provided for all continuous variables and frequencies for categorical variables. A subgroup analysis will be conducted in subjects with prior recurrence ≤1/yr and \<4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG). An interim analysis will be conducted after 1 year of study enrollment to evaluate safety, efficacy, and trial progress.
Impact on cancer Low recurrence in bladder cancer
295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.
This study's planned enrollment of 250 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Browse Non-Muscle Invasive Bladder Neoplasms studies →S. Andrea Hospital is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Cruciferae intake diet
Dietary Supplement: Cruciferae intake diet
Patients with normal diet
Dietary Supplement: Habituary dietary regimen
Patients in the intervention group will receive a dietary regimen characterized by high consumption of Cruciferae vegetables \[≥1 cup /day\] for 6 months. Patients in this group will receive educative booklets on the Cruciferae family of vegetables and visual charts on serving sizing to meet the recommended daily CV intake. Patients will be asked to record daily Cruciferae intake. They will receive a live phone call every week to verify their understanding of the educational information and the consistency of the dietary regimen.
Patients randomized in the control group will receive standard of care (SOC) without any modification of the habitual dietary regimen.
Recurrence Free Survival
of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC).
Time frame: 24 months
Recurrence in BCa
Recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer
Time frame: 24 months
ITC levels
To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels.
Time frame: 24 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Results will be published in an original article
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Two years
Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-Muscle Invasive Bladder Neoplasms →
S. Andrea Hospital